Water at 1 in 10 U.S. Beaches Fails to Make the Grade
If you swim at 10 different U.S. beaches, you could end up getting a stomach bug, conjunctivitis or even something more serious from one of them. New research has concluded that 10% of the country’s coastal and lakefront beaches fail to meet the Environmental Protection Agency’s water-safety standards — in other words, they’re ripe with bacteria.
Things are particularly bad in New England, on the Gulf Coast and along the Great Lakes, according to the data.
The major culprit is stormwater runoff, which inevitably ends up in the ocean after picking up garbage, oil and waste products from both humans and animals a...
Source: TIME.com: Top Science and Health Stories - June 26, 2014 Category: Consumer Health News Authors: Nash Jenkins Tags: Uncategorized atlantic Environment gulf coast Oceans Pacific Pollution U.S. Source Type: news
Pink Eye (Conjunctivitis)
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 23, 2014 Category: Journals (General) Source Type: news
Tacrolimus Eye Drops for Refractory Allergic Ocular DiseasesTacrolimus Eye Drops for Refractory Allergic Ocular Diseases
Use of tacrolimus 0.1% eye drops is associated with significant improvement of refractory allergic conjunctivitis with proliferative lesions and/or corneal involvement, according to an observational study from Japan. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - April 22, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news
FDA Approves Sublingual Ragweed Allergy Treatment (FREE)
By the Editors
The FDA has approved Ragwitek to treat hay fever, with and without conjunctivitis, caused by … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 18, 2014 Category: Primary Care Source Type: news
FDA Approves Merck’s RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults
Dateline City:
WHITEHOUSE STATION, N.J.
RAGWITEK is the First and Only FDA Approved Sublingual Allergen Immunotherapy Tablet Indicated for the Treatment of Short Ragweed Pollen Allergies
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for
Sublingual Use (12 Amb a 1-U)...
Source: Merck.com - Corporate News - April 17, 2014 Category: Pharmaceuticals Tags: Prescription Medicine News Corporate News Latest News Source Type: news
FDA approves Ragwitek for short ragweed pollen allergies
The U.S. Food and Drug Administration today approved Ragwitek, the first allergen extract administered under the tongue (sublingually) to treat short ragweed pollen induced allergic rhinitis (hay fever), with or without conjunctivitis (eye inflammation), in adults 18 years through 65 years of age. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 17, 2014 Category: American Health Source Type: news
FDA OKs Sublingual Grastek for Timothy Grass Pollen AllergyFDA OKs Sublingual Grastek for Timothy Grass Pollen Allergy
The FDA approved a grass pollen allergen extract for the treatment of Timothy grass pollen-induced allergic rhinitis, with or without conjunctivitis, in individuals aged 5 to 65 years. FDA Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 15, 2014 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Alert Source Type: news
FDA Approves Merck’s GRASTEK® (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults
Dateline City:
WHITEHOUSE STATION, N.J.
GRASTEK is the Only FDA Approved Sublingual Allergy Immunotherapy Tablet Indicated for Children as Young as 5 Years of Age
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved GRASTEK® (Timothy Grass Pollen Allergen Extract)
Tablet for Sublingual Use [2800 Bioequivalent Allergy Units (BAU)].
...
Source: Merck.com - Corporate News - April 14, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Sublingual Immunotherapy Approved for Grass Allergies (FREE)
By Kristin J. Kelley
The FDA has approved the first sublingual allergen extract to treat rhinitis — with or without conjunctivitis — caused by grass pollens. The once-daily tablet (Oralair) is … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 3, 2014 Category: Primary Care Source Type: news
FDA approves first sublingual allergen extract for the treatment of certain grass pollen allergies
The U.S. Food and Drug Administration recently approved Oralair to treat allergic rhinitis (hay fever) with or without conjunctivitis (eye inflammation) that is induced by certain grass pollens in people ages 10 through 65 years. Oralair is the first sublingual (under the tongue) allergen extract approved in the United States. After administration of the first dose at the health care provider’s office, where the patient can be observed for potential adverse reactions, Oralair can be taken at home. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 2, 2014 Category: American Health Source Type: news
Stallergenes obtains US FDA approval for pollen allergy drug Oralair
France-based Stallergenes has secured US Food and Drug Administration (FDA) approval for its immunotherapy tablet Oralair for treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 1, 2014 Category: Pharmaceuticals Source Type: news
Azithromycin Eye Drops for Purulent Bacterial Conjunctivitis in ChildrenAzithromycin Eye Drops for Purulent Bacterial Conjunctivitis in Children
Azithromycin 1.5% eye drops twice daily appears to clear purulent bacterial conjunctivitis in children faster than tobramycin 0.3% every two hours. Reuters Health Information (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 31, 2014 Category: Drugs & Pharmacology Tags: Ophthalmology News Source Type: news
So You Think You Have Pinkeye
Spring blooms mixed with lingering winter germs create the perfect scene for pinkeye. Conjunctivitis, as it is technically known, can actually take three forms. One expert gives his opinion on how to treat it. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 17, 2014 Category: Pharmaceuticals Tags: FREE Source Type: news
Oral Immunotherapy Reduces Sensitivity to Dust MitesOral Immunotherapy Reduces Sensitivity to Dust Mites
An experimental sublingual tablet cut nasal symptoms by half and conjunctivitis by two thirds in early investigation, say researchers. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 6, 2014 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Is Zika on our Doorstep?
Three months ago, most people had never heard of the Zika virus. Today, it makes global headlines on a daily basis. Earlier this month, the World Health Organization (WHO) declared a ‘public health emergency of international concern,’ marking only the fourth time an outbreak has been given such a designation in WHO’s history. The label is given to extraordinary events that endanger public health and constitute a risk to other states through the worldwide spread of a disease and potentially require a coordinated, international response. Even though the Zika virus has been known since 1947, the alarm has only been soun...
Source: WHO EMRO News - February 18, 2014 Category: Middle East Health Source Type: news
